These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21467260)

  • 1. Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Peterson GM; Naunton M; Tichelaar LK; Gennari L
    Ann Pharmacother; 2011 Apr; 45(4):499-509. PubMed ID: 21467260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
    Gennari L
    Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lasofoxifene: CP 336156, CP-336156.
    Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
    Gennari L
    Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasofoxifene for postmenopausal women with osteoporosis.
    Katzeff BS
    N Engl J Med; 2010 Jun; 362(23):2227-8; author reply 2228-9. PubMed ID: 20568309
    [No Abstract]   [Full Text] [Related]  

  • 7. Lasofoxifene for postmenopausal women with osteoporosis.
    Silva-Fernández L; Andreu JL
    N Engl J Med; 2010 Jun; 362(23):2228; author reply 2228-9. PubMed ID: 20568310
    [No Abstract]   [Full Text] [Related]  

  • 8. Lasofoxifene (Pfizer).
    Gennari L
    Curr Opin Investig Drugs; 2005 Oct; 6(10):1067-78. PubMed ID: 16259229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
    Archer DF
    Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718
    [No Abstract]   [Full Text] [Related]  

  • 10. Lasofoxifene in postmenopausal women with osteoporosis.
    Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
    N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not all SERMs are created equal.
    Goldstein SR
    Menopause; 2006; 13(3):325-7. PubMed ID: 16735926
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene.
    Gennari L; Merlotti D; Nuti R
    Clin Interv Aging; 2010 Feb; 5():19-29. PubMed ID: 20169039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lasofoxifene in osteoporosis and its place in therapy.
    Swan VJ; Hamilton CJ; Jamal SA
    Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Another selective estrogen-receptor modulator for osteoporosis.
    Becker C
    N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
    [No Abstract]   [Full Text] [Related]  

  • 15. Lasofoxifene for postmenopausal women with osteoporosis.
    Malozowski S
    N Engl J Med; 2010 Jun; 362(23):2227; author reply 2228-9. PubMed ID: 20558377
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
    Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
    Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third-generation SERMs may face uphill battle.
    Schmidt C
    J Natl Cancer Inst; 2010 Nov; 102(22):1690-2. PubMed ID: 21060064
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Palacios S
    Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CP 336156.
    Drugs R D; 1999 Mar; 1(3):213-4. PubMed ID: 10566027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.